StreetInsider.com News Articles

Form EFFECT Ensysce Biosciences,

Mon, 29 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260629/26701454.html

Form EFFECT Ensysce Biosciences,

Mon, 29 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260629/26701454.html

Ensysce Biosciences begins final phase of opioid overdose study

Fri, 26 Jun 2026 08:02:17 -0400

Ensysce Biosciences, Inc. (NASDAQ: ENSC) announced the enrollment of the first patient in Part 3 of its PF614-MPAR-102 clinical study, marking the start of the final stage of testing for its Multi-Pill Abuse Resistance (MPAR) overdose-protection technology.

The drug candidate, PF614-MPAR, uses a chemical-control mechanism designed to deliver therapeutic opioid exposure at prescribed doses while restricting additional release when excessive doses are taken. Earlier clinical data showed the compound maintains consistent plasma levels at normal doses while limiting exposure increases at supratherapeutic levels.

Part 3 of the study is intended to further define this protective profile across a broader range of dosing

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

Fri, 26 Jun 2026 08:00:00 -0400

~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~

SAN DIEGO, CA / ACCESS Newswire / June 26, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today announced initiation of the final stage of the PF614-MPAR-102 clinical study. The study is evaluating its novel MPAR^® (Multi-Pill Abuse Resistance) overdose-protection technology.

Rather than relying on traditional abuse‑deterrent technologies, PF614‑MPAR is engineered to provide active protection

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

Fri, 26 Jun 2026 08:00:00 -0400

~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~

Rather than relying on traditional abuse‑deterrent technologies, PF614‑MPAR is engineered to provide active protection

Form S-3 Ensysce Biosciences,

Thu, 04 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260604/26606397.html

Form S-3 Ensysce Biosciences,

Thu, 04 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260604/26606397.html

Form 8-K Ensysce Biosciences, For: May 22

Fri, 22 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260522/26542634.html

Form 8-K Ensysce Biosciences, For: May 22

Fri, 22 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260522/26542634.html

Form 8-K Ensysce Biosciences, For: May 15

Fri, 15 May 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260515/26506106.html

Form 8-K Ensysce Biosciences, For: May 15

Fri, 15 May 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260515/26506106.html

Form 10-Q Ensysce Biosciences, For: Mar 31

Fri, 15 May 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260515/26506135.html

Form 10-Q Ensysce Biosciences, For: Mar 31

Fri, 15 May 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260515/26506135.html

Ensysce Biosciences Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 16:15:00 -0400

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~

~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~

~ Company Launches Formal Review of Strategic Alternatives ~

SAN DIEGO, CA / ACCESS Newswire / May 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today reported financial and operational results for the first quarter ended March 31, 2026.

"The first quarter of 2026 delivered meaningful operational and clinical

Ensysce Biosciences Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 16:15:00 -0400

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~

~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~

~ Company Launches Formal Review of Strategic Alternatives ~

"The first quarter of 2026 delivered meaningful operational and clinical

Ensysce Biosciences receives Taiwan patent for overdose protection technology

Tue, 12 May 2026 08:09:29 -0400

Ensysce Biosciences Inc. (NASDAQ: ENSC) announced that the Taiwan Intellectual Property Office issued a patent covering the company's MPAR overdose protection technology. The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof," provides protection through 2042 in Taiwan and expands upon a U.S. patent issued on April 14, 2026.

The MPAR (Multi-Pill Abuse Resistance) technology has received Breakthrough Therapy designation from the U.S. Food and Drug Administration. Clinical studies showed that PF614-MPAR provided pain relief when used as directed while preventing excessive opioid release when multiple doses were taken. The company has extended the technology

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Tue, 12 May 2026 08:00:00 -0400

~ Patent Extends Jurisdiction and Protection Through 2042 ~

SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Taiwan Intellectual Property Office issued a patent covering Ensysce's MPAR^® (Multi-Pill Abuse Resistance) technology. The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof", includes both composition-of-matter and method-of-use claims that strengthen Ensysce's

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Tue, 12 May 2026 08:00:00 -0400

~ Patent Extends Jurisdiction and Protection Through 2042 ~

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

Fri, 08 May 2026 08:00:00 -0400

~ Chemical Control, Clinical Confidence: Rethinking Opioids ~

SAN DIEGO, CA / ACCESS Newswire / May 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, announced that CEO, Dr. Lynn Kirkpatrick, presented as an invited speaker and was featured on a panel at the first Pain Therapeutics Summit Europe held in Amsterdam May 7-8, 2026.

This meeting gathered experts from around the world to discuss latest advancements in analgesic care,

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

Fri, 08 May 2026 08:00:00 -0400

~ Chemical Control, Clinical Confidence: Rethinking Opioids ~

This meeting gathered experts from around the world to discuss latest advancements in analgesic care,

Form S-8 Ensysce Biosciences,

Thu, 30 Apr 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260430/26408443.html

Form S-8 Ensysce Biosciences,

Thu, 30 Apr 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260430/26408443.html

Ensysce receives approval for final phase of opioid overdose study

Thu, 16 Apr 2026 08:04:00 -0400

Ensysce Biosciences Inc. (NASDAQ: ENSC) announced it received Investigational Review Board approval to begin Part 3 of the PF614-MPAR-102 clinical study, the final stage of testing for its overdose-protection technology.

The study evaluates PF614-MPAR, an opioid formulation that received Breakthrough Therapy designation from the U.S. Food and Drug Administration. The drug uses what the company calls Multi-Pill Abuse Resistance technology, designed to maintain therapeutic opioid levels during prescribed use while limiting additional opioid release when excessive doses are taken.

According to previously published clinical data, PF614-MPAR delivers consistent plasma levels under normal dosing while reducing opioid exposure at higher-than-prescribed doses. Part 3

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

Thu, 16 Apr 2026 08:00:00 -0400

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~

SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today announced Investigational Review Board (IRB) approval to initiate Part 3 of the PF614-MPAR-102 clinical study, marking the final stage in this study evaluating its novel MPAR^® (Multi-Pill Abuse Resistance) overdose-protection technology.

PF614-MPAR, which received Breakthrough Therapy designation from the U.S. FDA following the PF614-MPAR-101 study,

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

Thu, 16 Apr 2026 08:00:00 -0400

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~

PF614-MPAR, which received Breakthrough Therapy designation from the U.S. FDA following the PF614-MPAR-101 study,